B-B4-DM1

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameB-B4-DM1
Drug Alias NameCD138-targeted MAb-DM1 conjugate (Immunogen)CD138-targeted MAb-DM1 conjugate (sanofi-aventis)CD138-targeted MAb-DM1 conjugate (Aventis)B-B4-DM1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionTubulin inhibitorsSyndecan-1 inhibitors
TargetsTubulinSyndecan-1
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAventisImmunogen Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A